Targeting nuclear catenin as therapy for postmyeloproliferative neoplasm secondary AML

Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML

01:18 EST 22 Dec 2018 | Nature Publishing

More From BioPortfolio on "Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML"